NICE recommends ORGOVYX® as the first oral ADT treatment for hormone sensitive prostate cancer in England

Accord Healthcare United Kingdom England

NICE has today published its final positive guidance recommending the use of relugolix for NHS England, acknowledging it as a cost-effective treatment option for patients with hormone sensitive prostate cancer.1Relugolix is recommended, within its marketing authorisation, as an option for treating prostate cancer in adults:1with advanced hormone-sensitive prostate canceralongside radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate canceras neoadjuvant treatment before radiotherapy for high-risk localised or locally advanced hormone-sensitive prostate cancerRelugolix is an oral androgen deprivation therapy (ADT). This decision by NICE means those living with prostate cancer can now have a choice between receiving either an oral or injectable ADT.Last Accessed August 2024
3 Cancer Research UK. Prostate Cancer statistics. Available at https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer#heading-Zero Last Accessed August 2024
4 Cancer Research UK. What is hormone therapy for prostate cancer. Available at https://www.cancerresearchuk.org/about-cancer/prostate-cancer/treatment/hormone-therapy/about-hormone-therapy#:~:text=Prostate%20cancer%20usually%20depends%20on,have%20it%20with%20other%20treatments. Last Accessed August 2024
5 Cleveland clinic. Chemical castration: Treatment, Procedure & Side Effects. Available at: https://my.clevelandclinic.org/health/treatments/22402-chemical-castration Last accessed August 2024.
6 Shore, Neal D., et al. "Oral relugolix for androgen-deprivation therapy in advanced prostate cancer." New England Journal of Medicine 382.23 (2020): 2187-2196
7 Medicines & Healthcare products Regulatory Agency. Public Assessment Report. Available at https://mhraproducts4853.blob.core.windows.net/docs/a027a8efa27937234d149e3577bc4b983840ad5b Last accessed August 2024

View original content:https://www.prnewswire.co.uk/news-releases/nice-recommends-orgovyx-relugolix-as-the-first-oral-adt-treatment-for-hormone-sensitive-prostate-cancer-in-england-302222244.html

@ prnewswire.co.uk